Nordicus Partners 10-K Flags Going Concern, $4M Loss, and Control Weaknesses
NORD has more than doubled off its 52-week low of $1.25.
Summary
Nordicus Partners' 10-K discloses a going concern warning from its auditor, a $4.0 million net loss, and ineffective internal controls. With just $20,878 in cash, the pre-revenue biotech urgently needs additional funding.
Key Events · Earnings and Guidance · NORD
-
Going Concern Warning
Substantial doubt about the company's ability to continue as a going concern is raised in the auditor's report and Note 3, which point to an accumulated deficit of $50.8 million and a cash balance of just $20,878 as of March 31, 2026.
-
Financial Results
For fiscal 2026, the company posted a net loss of $4.0 million on zero revenue. Operating expenses reached $4.4 million, including $1.6 million in R&D, while cash used in operations totaled $4.3 million.
-
Internal Control Weakness
Management determined that disclosure controls and internal control over financial reporting were not effective, citing limited resources within the finance and accounting functions.
-
Director Resignation
After the fiscal year-end, director Andrew J. Ritter resigned from the board and all committees effective July 7, 2026, reducing the board's oversight capacity.
Analysis · NORD · Trade & Services
The annual report reveals that the auditor has raised substantial doubt about the company's ability to continue as a going concern. With only $20,878 in cash and an accumulated deficit of $50.8 million, cash burn is severe—$4.3 million was consumed by operations this year. Management also acknowledged that internal controls over financial reporting are ineffective, a consequence of limited accounting resources. For a pre-revenue biotech that depends on frequent capital raises, these are critical warning signs. Adding to governance uncertainty, director Andrew Ritter, who chaired the compensation committee, resigned after year-end. Survival now hinges on the company's ability to secure additional funding, likely through further dilutive stock sales.
At the time of this filing, NORD was trading at $2.50 on OTC in the Trade & Services sector, with a market capitalization of approximately $47.2M. The 52-week trading range was $1.25 to $10.16. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.